SCHEMBL420408

SCHEMBL420408

NNS(=O)(=O)c1ccccc1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.51
KAT6A Q92794 6/20 0.50
ALDH1A1 P00352 2/20 0.49
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
EDNRA P25101 2/20 0.45
PTGES2 Q9H7Z7 1/20 0.45
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
GFER P55789 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
EDNRB P24530 1/20 0.43
SLC22A12 Q96S37 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427884 0.84 CA1 (0.48) KMT2AMEN1GAAGFER
SCHEMBL5556357 0.83 PTGES2 (0.58) GBA1KAT6AALDH1A1PTGES2SLC22A12
SCHEMBL1028459 0.82 KAT6A (0.53) GBA1KAT6AALDH1A1PSEN1PSEN2
SCHEMBL6239644 0.80 CCR4 (0.46) GBA1PTGES2
SCHEMBL6239903 0.80 SLC40A1 (0.50) GBA1KAT6AALDH1A1KMT2AEDNRA
SCHEMBL8779451 0.80 KAT6A (0.51) GBA1KAT6AALDH1A1PSEN1PSEN2
SCHEMBL1621373 0.78 ALDH1A1 (0.67) GBA1KAT6AALDH1A1PSEN1PSEN2
SCHEMBL1767641 0.78 CA1 (0.56) GBA1KAT6AALDH1A1PSEN1PSEN2
SCHEMBL15973217 0.78 KAT6A (0.50) GBA1KAT6AALDH1A1PSEN1PSEN2
SCHEMBL24385370 0.77 KAT6A (0.49) GBA1KAT6AALDH1A1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320523-B1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER LAMBERT CO (US) 2005-06-22 EP claimed
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY LLC 2005-01-06 US claimed
EP-1320523-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Warner-Lambert Company LLC (US) 2003-06-25 EP claimed
WO-2002024672-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2002-03-28 WO claimed
CN-119462587-A Flavone-containing acylhydrazone compounds, and preparation method and application thereof 贵州大学 2025-02-18 CN disclosed
CN-118184582-A 4-Seleno-1-benzenesulfonyl pyrazole compound and electrochemical synthesis method and application thereof 延安大学 2024-06-14 CN disclosed
EP-4335439-A2 COMPOUNDS CTXT PTY LTD (AU) 2024-03-13 EP disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
EP-4299135-A2 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2024-01-03 EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 EP disclosed
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2023-11-09 US disclosed
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2023-11-09 US disclosed
US-4327196-A USING SULFONYL HYDRAZIDE BLOWING AGENTS, PEROXIDE CURING AGENTS FOR SIMULTANEOUS FOAMING AND CURING UNIROYAL, INC. (US) 1982-04-27 US disclosed
US-4256896-A THIAZOLE, IMIDAZOLINE, AND OXAZOLINE DYES; DISPERSE DYES; ANIONIC DYES; TEXTILES CIBA-GEIGY AKTIENGESELLSCHAFT (DE) 1981-03-17 US disclosed
US-4246422-A Naphtholactam dyestuffs CIBA-GEIGY AG (CH) 1981-01-20 US disclosed
US-4246410-A BENZINDOLE DYES OF YELLOW AND RED CIBA -GEIGY AKTIENGESELLSCHAFT (CH) 1981-01-20 US disclosed
US-4236007-A YELLOW SHADES ON POLYESTERS CIBA-GEIGY AKTIENGESELLSCHAFT (CH) 1980-11-25 US disclosed
US-4180665-A Substituted 3-benz(cd)indol-2-(1H)-ylidene-furo[2,3-b]quinoxalin-2(3H)one dyestuffs CIBA-GEIGY AKTIENGESELLSCHAFT (CH) 1979-12-25 US disclosed
US-4159379-A Dispersion dyestuffs of the naphtholactam series CIBA-GEIGY AG (CH) 1979-06-26 US disclosed
US-4146541-A YELLOW SHADE ON POLYESTERS CIBA-GEIGY AG (CH) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A GBA1 2596/4885KAT6A 3/4885ALDH1A1 2786/4885
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases BCAT1, BCAT2, ABAT GBA1 247/4885KAT6A 1615/4885ALDH1A1 642/4885
US-11911372-B2 Compounds SLC10A1, ABCB11, REN GBA1 102/4885KAT6A 951/4885ALDH1A1 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.